Prostatic carcinoma (CaP) is a major cause of male cancer mortality worldwide, and together with benign prostatic hyperplasia (BPH) represents a common cause of discomfort in elderly men. These two pathologies are characterised by a high degree of tissue heterogeneity. The ratio of prostatic cancer cells to normal glandular or stromal cells varies widely between biopsies. A morphometric analysis of 50 patients with prostatic carcinoma revealed the presence of cancer cells in 23%, stromal tissue in 72% and normal or BPH glandular cells in 4% of all biopsy specimens examined (Bartsch et al., 1989) . Histological grading, tumour size, malignancy and serum prostate-specific antigen (PSA) levels are currently the most reliable tools for prostate cancer diagnosis.
To determine the prognosis of a particular tumour, molecular markers, such as gene mutations associated with the cancer progression, probably offer the most exciting prospect in the field of cancer research (Fearon and Vogelstein, 1990) . The ability to analyse these markers depends not only upon optimised procedures to detect a mutation, but also on the proportion of the sample which contains this mutation. Prostate cancer is characterised by a remarkably low frequency of alterations in genes known to be associated with other malignancies such as ras, myc, erbB-2, TP53, RB (Bishop, 1991) . Given the heterogeneity of biopsies, these low frequencies could stem from a failure to detect mutations actually present within prostatic carcinoma. So far, no oncogenes have been conclusively correlated with the CaP initiation or progression, and this raises the question of how to bypass the unavoidable contamination of 'tumour biopsies' by presumed non-malignant cells (for recent reviews see Buttyan et al., 1993; Lisitsyn et al., 1993) .
The gene encoding the tumour-suppressor protein TP53 is the most frequently affected gene in human cancer, where loss of both alleles has been observed, once through deletion, the other through point mutation (Levine et al., 1991 (Isaacs et al., 1991; Effert et al., 1992 Effert et al., , 1993 Bookstein et al., 1993; Navone et al., 1993; Uchida et al., 1993; Dinjens et al., 1994; Voeller et al., 1994) . By using an immunohistochemical method, several groups reported frequencies of abnormal TP53 accumulation in 6-79% of the prostate cancer samples (Soini et al., 1992; Visakorpi et al., 1992; Zhang et al., 1992; Van Veldhuizen et al., 1993) . In contrast, the occurrence of TP53 mutations in benign prostatic hyperplasia has also been reported, suggesting that these alterations may happen early in the progression of prostate cancer (Meyers et al., 1993 DNA extraction was carried out by boiling the sample for 15 min in the presence of 250 mg ml-' chelating resin (iminodiacetic acid, 50-100 mesh, Sigma), 1 mM sodium hydroxide in a final volume of 100 fil covered by one drop of mineral oil (after Singer-Sam et al., 1989) . After centrifugation at 15000 g for 5 min, the DNA solution was processed for PCR.
PCR of the exons 5/6 of the TP53 gene Oligonucleotide primers were selected to the target TP53 sequences using the Primer Designer Program (Scientific and Educational Software, PA, USA) at bp 13 030 for the sense primer (5'-CTCTGTCTCCTTCTTCTTCC-3') and bp 13 437 for the anti-sense primer (5'-CAGACCTCAGGCGGCTC-ATA-3'), amplifying a product of 407 bp covering both exons 5 and 6, and including the 90 bp intronic segment. The primers were synthesised in a DNA synthesiser (PCR-Mate, Applied Biosystems, model 391) and subsequently purified, based on trityl group affinity. The PCR reaction mixture contained 10 mM Tris-HCI pH 8.8, 50 mM potassium chloride 1.5 mM magnesium chloride, 200 iLM each of dATP, dGTP, dTTP and dCTP, and 2.6 tLM of each 20 base primer. A master mix containing all the above components and 2.5 U/ reaction of Taq polymerase (Taq XL, Northumbria Biologicals, UK) was prepared. The reaction was initiated by adding 10 ll of the sample DNA (150 pg DNA) to 40 ftl of the master mix, overlaid with one drop of mineral oil. The tubes were transferred to a Perkin Elmer Cetus thermocycler and treated as follows: 94°C for 4 min, then 40 cycles of 94°C, 55°C, 72°C of 1 min each, followed by a final extension step of 72°C for 7 min. Positive and negative controls were run in parallel to monitor the absence of contamination (an important factor when using microdissected material). The amplification products were separated by 1.5% agarose gel electrophoresis, and the product size determined relative to a 100 bp ladder (Pharmacia).
SSCP analysis
Analysis was carried out essentially as described by Hayashi (1991). The PCR products were labelled with [32P]-dATP (sp. ac. 3000 Ci mmol ', Amersham) by Taq polymerase for 10 cycles under the same conditions as above. Samples for SSCP were prepared for loading as follows: each sample was adjusted to 80 000 c.p.m. in a final volume of 10 ftl with 0.1% sodium dodecyl sulphate (SDS), 1O mM EDTA, mixed with 15 tl of 95% formamide, 20 mM EDTA, 1% xylene cyanol/bromphenol blue, heated at 70°C for 10 min and finally chilled on ice before loading to the gel. The SSCP gels were made up of 17% Hydrolink MDE (AT Biochem, Malvern, PA, USA), 53 mM Tris-borate pH 8.3, 1.2 mM sodium EDTA, 1.8 mM ammonium persulphate, 400 M TEMED, using non-siliconised plates with 0.4 mm spacers. After polymerisation, the wells were washed with 53 mM Tris-borate pH 8.3, 1.2 mM sodium EDTA (running buffer), samples loaded and the gels run for 7-8 h on 8 W constant Prostate cancer microdissection for molecular analysis P Berthon et al 947 power, then dried and exposed overnight at -80°C on Hyperfilm MP (Amersham).
Construction of TP53 insertional mutant
A PCR product corresponding to exons 5/6 of the normal TP53 allele was prepared as described above, purified by preparative gel electrophoresis and isolated by chromatography on DEAE paper. After extraction and purification, the product was cloned directly in pT7Blue T-vector (Novagen, Madison, WI, USA). The TP53 clone was then linearised by Nco-l at position 13 155 of the TP53 gene, which cut at a single site within the TPS3 insert and the linearised plasmid DNA. The band was cut out of the gel and purified using the Geneclean II kit (BIO 101, La Jolla, CA, USA). The Nco-I site was then filled in using Klenow polymerase and religated to produce a four base pair insertion in the TP53 insert.
Results
To quantitatively determine the detection threshold for a mutant TP53 allele in a background of normal alleles, we mixed an insertion mutation of TP53 with its normal counterpart at given ratios and submitted the mixture to PCR amplification and SSCP analysis (Figure 1 ). The insertion mutant was chosen for clarity of presentation, and similar results were obtained with point mutations, which form the majority of TPS3 mutants in vivo. In this system, the mutated signal only appeared consistently at mutant-normal allele ratios betwen 1:4 and 1:9 (and vice versa for the normal allele in the presence of excess mutant). Both alleles were amplified with approximately equal efficiency in multiple experiments.
To reduce the contribution of normal alleles from nontumour tissue to the PCR amplification reaction, we have developed a microdissection technique. As shown in Figure 2 , it was possible to take samples of well-documented cancer foci and to process them for further analysis. Preliminary experiments showed that using the primer set for TPS3 exons 5-8, it was possible to amplify genomic DNA from as little as 36 pg (not shown). This amount of DNA represents the content of three human cells. Furthermore, our aims were not only to microdissect cancerous areas but also to obtain normal stroma from the same biopsy section as an internal control (Figure 2) . By using this technique, we were able to prepare enough DNA to carry out 10-20 PCR/SSCP analyses from a single microdissection, which covers most of the needs for the screening of one complete gene, although different primer pairs may vary in their relative abilities to amplify particular mutants. To illustrate the procedure, we then analysed the state of the TP53 gene in two prostate cancer specimens (9317 and 9318) which showed no reactivity after immunoperoxidase staining and immunofluorescence with monoclonal DO-1, which binds to the N-terminus of denaturated stable TPS3 (Vojtesek et al., 1992) , PAb 1620, which is TP53 wild-type-specific (Ball et al., 1984; Milner et al., 1987) , PAb421, reacting with the C-terminus of TPS3 Figure 2 Microdissection of selected human prostatic epithelial tumour cells and stroma in situ. Within the same frozen/fixed/ stained section, microdissection of selected areas representing the pathological features of prostate cancer (left, epithelium microdissection) and the stromal cells considered to be normal (right, stroma microdissection) were performed using micropipettes and micromanipulator (see Materials and methods). The different microdissection steps are shown x 400 (before, during, after) on a section of a prostate cancer specimen scored 6 (3 + 3) according to Gleason grading. These selected microdissected foci were located within an assigned grade 3 area. The (x 100) magnification photography shows both selected areas located in close proximity, on the same section. Figure 3 SSCP analysis of prostate cancer specimens for TP53 exons 5/6 PCR products. PCR and SSCP analyses were carried out with a crude DNA extract from fragment of tissue biopsy (top) but also DNA extracted from microdissected epithelial and stromal areas (bottom) of carcinoma of the prostate (CaP) specimens 9317 and 9318 (see Materials and methods). While the profile of the whole tissue biopsies did not show any changes from normal, the microdissected epithelial patterns revealed extra bands which were subsequently analysed for presence of mutations. The epithelium band shifts for the CaP 9318 bands (1) and (2) were DNA sequenced using a new method for specific determination of mutation in heterogeneous SSCP profile (Figure 4) . The control for TP53 is the normal counterpart clone of the TP53 insertional mutant constructed for the competition assay as shown in Figure 1 . The prostate cancer cell line PC-3 run in parallel possesses only one allele of TP53 carrying a nonsense mutation within the codon 138 of exon 5 (Isaacs et aL, 1991). (Harlow et al., 1981) and PAb 240, which recognises a hidden amino acid motif in wild-type TP53 (Gannon et al., 1990 ; data not shown). Histopathologically, these tissues were reported with a Gleason score of 6 (3 + 3), and in each sample, a grade 3 tumour focus was selected and microdissected (Figure 2 ). In parallel, microdissection of an area of the surrounding stroma was carried out. A DNA preparation from the total biopsy was also processed for TP53 mutations.
As shown in Figure 3 , SSCP analysis of the PCR product obtained from the gross DNA extraction of prostate carcinoma tissues 9317 and 9318, only revealed a band pattern corresponding to normal TP53 alleles. On the other hand, from the microdissected areas, the SSCP gel showed extra bands for the epithelial cells, which were absent in the stroma. Apart from the appearance of extra bands, the normal TP53 pattern was also present in the microdissected epithelium 9317 and 9318, which may suggest either a residual heterogeneity of the cell area taken, or perhaps that the tumour cells contain one normal and one mutant TP53 copy. We consistently found in these experiments that the strength of the PCR signal from the 'normal allele' was greater than that from the mutant. By comparison, the prostate cancer cell line PC-3, showed a completely different band shift compared with the normal control (Figure 3 ). This cell line has been shown to contain only one allele of TP53, with a nonsense mutation at codon 138 (Isaacs et al., 1991) .
To determine if an observed band shift for TP53 exons 5/6 is indicative of a mutation, the normal and abnormal bands were extracted from the SSCP gel and directly sequenced after a second amplification by PCR. In Figure 3 using the specimen 9318, the SSCP bands labelled 1 and 2 were checked for mutations. While band 1 did not show any abnormality within the sequence, a point mutation was revealed in band 2, considered as abnormal by comparison with the normal migration pattern of TP53 exons 5/6 in SSCP. Other minor species, when reamplified and sequenced, were wild type, and presumably represent alternative minor conformations adopted in the SSCP gel. The mutation was detected at position 13 336 of the TP53 gene, and results in a missense mutation glutamine+ histidine at codon 192 within exon 6 of the TP53 protein (Figure 4) .
The DNA processed to obtain the data reported above was prepared from freshly fixed and haematoylin-eosin-stained frozen sections. We have also successfully extracted wellconserved DNA, for the purpose of PCR/SSCP analysis, from sections which have been previously immunostained using standard avidin-biotin-peroxidase detection, counterstained with haematoxylin, mounted under commercially available aqueous mounting media and then demounted for final processing. These sections had been stored at room temperature for up to 6 months. Furthermore, formalin-fixed and paraffin-embedded sections also produced similar results to freshly frozen/fixed sections, although it is clear that freshly fixed tissues give superior results, particularly for the amplification of DNA fragments greater than 500 bp (not shown). DNA has also been recovered from 10-year-old archival tissue, but we have no doubt it is possible to extract DNA from much older stored tissues.
Discussion
The purpose of this study was to develop a reliable molecular analysis using homogeneous cell populations selected from prostatic carcinomas, to avoid masking of tumour-specific genetic changes by normal and reactive cells within the tumour specimens. Despite careful biopsy technique and crude microdissections, it has been almost impossible to obtain homogeneous prostatic carcinoma tissue, to determine molecular events involved in tumour development and progression (Sarkar et al., 1993) .
Tissue heterogeneity makes it difficult to assess how many copies of an abnormal gene are present compared with the number of normal copies. This heterogeneity raises questions about the reliability of results obtained from whole tissue DNA preparations, in which the signal from mutant alleles may be masked by the presence of normal alleles, and the results of the reconstruction experiment (Figure 1) By developing a precise microdissection technique, we are therefore able to analyse archival biopsies from patients who initially present with benign prostatic disorders which may progress to malignancy. However, with increased precision, there is also the possibility of intra-and inter-sample cross contamination, which can be ignored in most larger scale analyses of human genes by PCR. Experience in the detection of latent viral infections (Maitland and Lynas, 1991) , and minimal residual disease in leukaemia patients (Potter et al., 1992) underlines this concern. We have taken every reasonable precaution to avoid contamination, including UV treatment by cryosectioning blades, individual sterile slides, sterile microneedles discarded after each microdissection, and individual PCR quality reagents used in dedicated class 2 facilities. We are therefore confident that the presence of a strong normal TP53 allele signal in the SSCP analysis of dissected tumour tissues is not a result of crosscontamination. It could either be due to increased efficiency of amplification of the normal allele, or to the presence of normal cells, which are identical to. the tumour cells by both histological and immunocytochemical analysis, within the microdissected mass. Despite its frequent involvement in human cancer, the existence of TP53 mutation in prostate cancer remains unclear. Our experiments set out to study the feasibility of SSCP band shift as a method of measuring the frequency of mutation in the human TP53 gene exons 5/6, by PCR/SSCP analysis of microdissected prostate tissues containing histopathologically documented tumour foci. We chose these exons for a preliminary study since they are frequently mutated in human cancer. According to Caron de Fromentel and Soussi (1992) , exons 5 and 6 contain respectively, 28.5% and 12% of all p53 mutations, irrespective of the origin of the tumour.
Careful studies of documented tumour after microdissection should increase the observed frequency of many mutations, especially in prostate cancer when DNA abnormalities could neither be detected by crude DNA preparation and/or immunology. Our results emphasise the need for precise microdissection as part of a study of mutations in exons 5-8 of TP53 where almost 97% mutations have been located in human cancer (Cariello et al., 1994; Greenblatt et al., 1994; Hollstein et al., 1994) . It should also remove the uncertain and inconsistent results obtained in many of the current mutation studies with this tumour and other histologically heterogeneous tumours (Noguchi et al., 1992; Whetsell et al., 1992) . Such studies are of critical importance to establish the regulatory pathways which control stepwise progression leading to prostatic carcinoma.
